1. Home
  2. BMEA vs VRA Comparison

BMEA vs VRA Comparison

Compare BMEA & VRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.32

Market Cap

95.4M

Sector

Health Care

ML Signal

HOLD

Logo Vera Bradley Inc.

VRA

Vera Bradley Inc.

HOLD

Current Price

$4.03

Market Cap

111.2M

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMEA
VRA
Founded
2017
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Apparel
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
95.4M
111.2M
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
BMEA
VRA
Price
$1.32
$4.03
Analyst Decision
Strong Buy
Hold
Analyst Count
6
2
Target Price
$9.83
N/A
AVG Volume (30 Days)
959.9K
498.0K
Earning Date
05-12-2026
06-10-2026
Dividend Yield
N/A
N/A
EPS Growth
69.19
20.47
EPS
N/A
N/A
Revenue
N/A
$416,097,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.50
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$1.39
52 Week High
$2.99
$4.39

Technical Indicators

Market Signals
Indicator
BMEA
VRA
Relative Strength Index (RSI) 49.06 61.42
Support Level $1.23 $3.02
Resistance Level $1.48 $4.37
Average True Range (ATR) 0.10 0.17
MACD 0.01 0.00
Stochastic Oscillator 40.91 87.50

Price Performance

Historical Comparison
BMEA
VRA

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

About VRA Vera Bradley Inc.

Vera Bradley Inc designs women's handbags, luggage, and travel items, fashion and home accessories, and gifts. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct and Vera Bradley Indirect.

Share on Social Networks: